ribavirin has been researched along with bms-650032 in 41 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 37 (90.24) | 24.3611 |
2020's | 4 (9.76) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H | 1 |
Suk-Fong Lok, A | 1 |
Carifa, A; Eley, T; Falk, P; Fridell, R; Gardiner, D; Hernandez, D; McPhee, F; Monikowski, A; Ueland, J; Wang, C; Yu, F; Zhou, N | 1 |
Abrams, GA; Ahmad, A; Bourlière, M; Bronowicki, JP; Cohen, D; Eley, T; Fried, MW; He, B; Hézode, C; Hindes, R; Hughes, E; Larrey, D; Martorell, CT; Massoud, O; McPhee, F; Mendez, P; Morris, DW; Pol, S; Ratziu, V; Reddy, KR; Reilly, B; Rustgi, VK; Thuluvath, PJ; Younes, Z | 1 |
Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
Bourlière, M; Eley, T; Everson, GT; Gardiner, DF; Grasela, DM; Hézode, C; Huang, SP; Lawitz, EJ; Li, J; Lok, AS; Marcellin, P; McPhee, F; Pasquinelli, C; Pol, S; Rodriguez-Torres, M; Serfaty, L; Wind-Rotolo, M; Yu, F | 1 |
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
Bessone, F; Bronowicki, JP; Cohen, D; Eley, T; Gadano, A; He, B; Hernandez, D; Hughes, E; Martorell, CT; McPhee, F; Mendez, P; Pol, S; Ratziu, V; Terg, R; Thuluvath, PJ; Younes, Z; Yu, F | 1 |
Bertz, R; Bifano, M; Eley, T; Gardiner, D; Grasela, DM; He, B; Huang, SP; Kandoussi, H; Sevinsky, H; Zhu, K | 1 |
Arnold, ME; Aubry, AF; Baker, C; Burrell, R; Cojocaru, L; Demers, R; Easter, J; Eley, T; He, B; Jiang, H; Kadiyala, P; Kandoussi, H; Pursley, J; Ryan, J; Wang, J; Zeng, J | 1 |
Bernstein, D; Brunetto, M; de Ledinghen, V; Elkhashab, M; Everson, G; Hennicken, D; Heo, J; Hézode, C; Hughes, E; Jensen, D; Kugelmas, M; Luketic, V; Mauss, S; McPhee, F; Mendez, P; Noviello, S; Pol, S; Serfaty, L; Sherman, KE; Tran, A; Vierling, J; Younes, ZH; Zeuzem, S | 1 |
Cooper, J; Dore, GJ; Everson, G; Freilich, B; Ghesquiere, W; Herring, R; Hézode, C; Hughes, EA; Kwo, P; Lalezari, J; McPhee, F; Muir, AJ; Pockros, PJ; Poordad, F; Ramji, A; Reau, N; Sheikh, A; Stuart, K; Swenson, ES; Thompson, AJ; Tran, A; Vierling, J; Yang, R; Yin, PD; Yozviak, J | 1 |
Behl, AS; Betts, KA; Kalsekar, A; Li, J; Signorovitch, JE; Song, Y; Sorg, RA | 1 |
Boor, PP; de Jonge, J; de Ruiter, PE; Ijzermans, JN; Kwekkeboom, J; Metselaar, HJ; Tilanus, HW; van der Laan, LJ | 1 |
Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T | 1 |
Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C | 1 |
Desta, T; Eley, T; Everson, GT; Gardiner, DF; Gitlin, N; Grasela, DM; Hassanein, T; Hawkins, T; Hinestrosa, F; Huang, SP; Lawitz, E; Levin, JM; McPhee, F; Rodriguez-Torres, M; Rustgi, V; Schwartz, H; Sims, KD; Thuluvath, PJ; Webster, L; Younossi, Z | 1 |
Espinoza, MA; Giglio, A; Soza, A; Vargas, CL | 1 |
Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y | 1 |
Ghany, M; Keane, M; Liang, TJ; O'Keefe, AC; Park, H; Rehermann, B; Rivera, E; Serti, E | 1 |
Adachi, K; Ishii, T; Kumon, D; Matsumoto, N; Noguchi, Y; Okuse, C; Sato, A; Tamura, T | 1 |
Bae, SH; Chen, X; Chuang, WL; Garimella, T; Gong, G; Jia, J; Jia, Z; Li, Y; Lin, S; Lu, W; McPhee, F; Mo, L; Niu, J; Torbeyns, A; Treitel, M; Wei, L; Xie, Q; Xie, W; Xu, M; Yang, YF; Yin, PD; Zhang, M | 1 |
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
Cao, Y; Huo, N; Lu, H; Wu, C; Xu, X; Zhang, R; Zhang, X; Zhang, Y | 1 |
Chen, PJ; Hong, CM; Liu, CJ; Yeh, SH | 1 |
Yu, ML | 1 |
Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y | 1 |
Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S; Yoshida, K | 1 |
Harada, S; Iida, T; Koshino, K; Masuda, K; Matsuyama, T; Nakamura, T; Nobori, S; Ushigome, H; Yoshimura, N | 1 |
Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M | 1 |
Kim, HJ; Lee, HW; Won, JW; Yoo, KY | 1 |
Espinoza, MA; Giglio, A; Soza, A; Vargas, C | 1 |
Asselah, T; Bellissant, E; Bourlière, M; Bronowicki, JP; Canva, V; Diallo, A; Fontaine, H; Laforest, C; Leroy, V; Loustaud-Ratti, V; Ouzan, D; Petrov-Sanchez, V; Renault, A; Roulot, D; Rousseau, C; Schischmanoff, O; Serfaty, L; Thibault, V; Zoulim, F | 1 |
Chang, F; Duan, CA; Jin, X; Lu, Y | 1 |
Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML | 1 |
Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F | 1 |
Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
Jang, JY; Jun, DW; Jung, YK; Kim, MY; Kim, SG; Kwon, OS; Lee, JW; Lee, SH; Park, JY; Yoo, HW | 1 |
Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ | 1 |
5 review(s) available for ribavirin and bms-650032
Article | Year |
---|---|
HCV NS5A inhibitors in development.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Male; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
13 trial(s) available for ribavirin and bms-650032
Article | Year |
---|---|
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Diarrhea; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Japan; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2012 |
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
Topics: Adult; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2013 |
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2014 |
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoquinolines; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult | 2014 |
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Topics: Adult; Antiviral Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Young Adult | 2014 |
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2015 |
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Valine; Viral Load | 2015 |
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2016 |
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine; Viral Load | 2018 |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Taiwan; Valine; Viral Nonstructural Proteins | 2019 |
23 other study(ies) available for ribavirin and bms-650032
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.
Topics: Antiviral Agents; Benzazepines; Carbamates; Chromatography, Liquid; Hepacivirus; Humans; Imidazoles; Indoles; Interferons; Isoquinolines; Plasma; Pyrrolidines; Reproducibility of Results; Ribavirin; Sulfonamides; Tandem Mass Spectrometry; Valine | 2015 |
Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
Topics: Antiviral Agents; Biomarkers; Carbamates; Cell Line, Tumor; Dendritic Cells; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Isoquinolines; Liver Transplantation; Prednisolone; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.
Topics: Antiviral Agents; Carbamates; Chile; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Probability; Protease Inhibitors; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Valine; Viral Load | 2015 |
Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Phosphorylation; Pyrrolidines; Retreatment; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Sulfonamides; Sustained Virologic Response; TNF-Related Apoptosis-Inducing Ligand; Valine; Viral Load | 2017 |
Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Failure; Valine; Viral Load | 2016 |
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon Type I; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Pyrrolidines; Ribavirin; Risk Factors; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Base Sequence; Carbamates; China; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA Helicases; Sequence Analysis, DNA; Serine Endopeptidases; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sulfonamides; Taiwan; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2017 |
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Serine Proteases; Simeprevir; Sulfonamides; Time Factors; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferons; Isoquinolines; Kidney Transplantation; Male; Middle Aged; Prednisolone; Prospective Studies; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine | 2017 |
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Proportional Hazards Models; Pyrrolidines; Ribavirin; Risk Factors; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2017 |
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2017 |
Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno.
Topics: Antiviral Agents; Carbamates; Chile; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Public Health; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2017 |
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Topics: Adult; Antiviral Agents; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Markov Chains; Middle Aged; Monte Carlo Method; Polyethylene Glycols; Probability; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Valine | 2018 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine | 2020 |
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferons; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Seoul; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2022 |
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2023 |